Publications

BibTex format

@article{Palmieri:2017:10.1007/s10549-017-4427-x,
author = {Palmieri, C and Szydlo, R and Miller, M and Barker, L and Patel, NH and Sasano, H and Barwick, T and Tam, H and Hadjiminas, D and Lee, J and Shaaban, A and Nicholas, H and Coombes, RC and Kenny, LM},
doi = {10.1007/s10549-017-4427-x},
journal = {Breast Cancer Research and Treatment},
pages = {527--539},
title = {IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer},
url = {http://dx.doi.org/10.1007/s10549-017-4427-x},
volume = {166},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Steroid sulfatase (STS) is involved in oestrogen biosynthesis and irosustat is a first generation, irreversible steroid sulfatase inhibitor. A pre-surgical window-of-opportunity study with irosustat was undertaken in estrogen receptor-positive (ER+) breast cancer to assess the effect of irosustat on tumour cell proliferation as measured by 3'-deoxy-3'-[18F] fluorothymidine uptake measured by PET scanning (FLT-PET) and Ki67. METHODS: Postmenopausal women with untreated ER+ early breast cancer were recruited, and imaged with FLT-PET at baseline and after at least 2 weeks treatment with irosustat, 40 mg once daily orally. The primary endpoint was changed in FLT uptake; secondary endpoints included safety and tolerability of irosustat, changes in tumoral Ki67 and steroidogenic enzymes expression and circulating steroid hormone levels. RESULTS: Thirteen women were recruited, and ten started irosustat for 2 weeks, followed by repeat FLT-PET scans in eight. Defining response as decreases of ≥20% in standardized uptake value (SUV) or ≥30% in Ki, 1 (12.5% (95% CI 2-47%, p = 0.001)) and 3 (43% (95% CI 16-75%, p = <0.001) patients, respectively, responded. 6 out of 7 patients had a Ki67 reduction (range = -19.3 to 76.4%), and median percentage difference in Ki67 was 52.3% (p = 0.028). In one patient with a low baseline STS expression, a 19.7% increase in Ki67 was recorded. STS decreases were seen in tumours with high basal STS expression, significant decreases were also noted in aromatase, and 17β-hydroxysteroid dehydrogenase type 1 and 2. Irosustat was generally well tolerated with all adverse event CTCAE Grade ≤2. CONCLUSIONS: Irosustat resulted in a significant reduction in FLT uptake and Ki67, and is well tolerated. These data are the first demonstrating clinical activity of irosustat in early breast cancer. Baseline expression of STS may be a biomarker of sensitivity to irosustat.
AU  - Palmieri,C
AU  - Szydlo,R
AU  - Miller,M
AU  - Barker,L
AU  - Patel,NH
AU  - Sasano,H
AU  - Barwick,T
AU  - Tam,H
AU  - Hadjiminas,D
AU  - Lee,J
AU  - Shaaban,A
AU  - Nicholas,H
AU  - Coombes,RC
AU  - Kenny,LM
DO  - 10.1007/s10549-017-4427-x
EP  - 539
PY  - 2017///
SN  - 0167-6806
SP  - 527
TI  - IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer
T2  - Breast Cancer Research and Treatment
UR  - http://dx.doi.org/10.1007/s10549-017-4427-x
UR  - https://www.ncbi.nlm.nih.gov/pubmed/28795252
UR  - http://hdl.handle.net/10044/1/64157
VL  - 166
ER  -

Download

ProfessorCharlesCoombes

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)